Figure 5
Figure 5. GLI1 is a bona fide substrate of IKKβ. (A) 293T cells were transiently cotransfected with constructs carrying GLI1 and IKKβ wild-type. Cell lysates were incubated with or without calf intestinal alkaline phosphatase (CIP) and subjected to immunoblotting. The red arrow indicates phosphorylated GLI1 protein band. (B) Epitope-tagged expression vectors IKKβ or IKKβ-KD constructs were transfected into 293T cells. Immunoprecipitated kinase was assayed with affinity-purified GLI1 as a substrate in the presence of (γ32P) ATP. (C) To identify IKKβ-dependent GLI1 phosphorylation sites, we cotransfected FL-GLI1 and IKKβ constructs in 293T cells, and the GLI1-complex was purified using anti-GLI1 antibody. Purified samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and band representing GLI protein was cut and analyzed by nanospray ion trap mass spectrometry. Eight phosphorylation sites were identified in the C-terminal region of GLI1 (S543-548, S1071, and T1074) as shown in the schematic diagram. (D) Immunoblot analysis of phosphorylated GLI1 in 293T cells transiently transfected with indicated GLI1 mutant constructs and IKKβ. (E) GST-purified GLI1 fragment (GLI1F; 411aa-1106aa) or triple-mutant GLI1 fragment (GLI1FTM) protein was incubated with immunoprecipitated IKKβ kinase in the presence of (γ32P) ATP and analyzed by in vitro kinase assay. (F) Cycloheximide (CHX) chase analysis of GLI1 or indicated full-length GLI1TM construct was expressed in 293T cells in the presence or absence of CHX (60 μg/mL) for indicated time periods. After TNFα (20 μg/mL) stimulation, cell lysates from each time point were immunoblotted with anti-GLI1, anti-P-p65 (Ser536), and anti-p65 antibodies. (G) GLI1 luciferase reporter analysis of 293T cells transiently transfected with indicated constructs with or without TNFα stimulation for 6 hours. Results are normalized to Renilla luciferase and expressed as fold change in relative luciferase activity compared with control. Data represent the mean and standard deviation of 2 independent experiments (**P < .005). (H) FL-GLI1TM construct was transiently transfected in 293T cells. After 48 hours, cells were stimulated with TNFα (20 μg/mL) for 60 minutes after CHX (60 μg/mL) and MG132 (30 μg/mL) treatment of indicated time periods. Cell lysates from each time point were immunoblotted with anti-GLI1 antibody. (I) 293T cells were cotransfected with full-length GLI1 and GLI1TM mutant construct, and ITCH-IKKβ-GLI1 complex was purified using anti-IKKβ antibody and subjected to immunoblotting. Each component of GLI1 complex immunoblots were analyzed by densitometry, normalized with IKKβ, and plotted to determine normalized ITCH/GLI1 association.

GLI1 is a bona fide substrate of IKKβ. (A) 293T cells were transiently cotransfected with constructs carrying GLI1 and IKKβ wild-type. Cell lysates were incubated with or without calf intestinal alkaline phosphatase (CIP) and subjected to immunoblotting. The red arrow indicates phosphorylated GLI1 protein band. (B) Epitope-tagged expression vectors IKKβ or IKKβ-KD constructs were transfected into 293T cells. Immunoprecipitated kinase was assayed with affinity-purified GLI1 as a substrate in the presence of (γ32P) ATP. (C) To identify IKKβ-dependent GLI1 phosphorylation sites, we cotransfected FL-GLI1 and IKKβ constructs in 293T cells, and the GLI1-complex was purified using anti-GLI1 antibody. Purified samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and band representing GLI protein was cut and analyzed by nanospray ion trap mass spectrometry. Eight phosphorylation sites were identified in the C-terminal region of GLI1 (S543-548, S1071, and T1074) as shown in the schematic diagram. (D) Immunoblot analysis of phosphorylated GLI1 in 293T cells transiently transfected with indicated GLI1 mutant constructs and IKKβ. (E) GST-purified GLI1 fragment (GLI1F; 411aa-1106aa) or triple-mutant GLI1 fragment (GLI1FTM) protein was incubated with immunoprecipitated IKKβ kinase in the presence of (γ32P) ATP and analyzed by in vitro kinase assay. (F) Cycloheximide (CHX) chase analysis of GLI1 or indicated full-length GLI1TM construct was expressed in 293T cells in the presence or absence of CHX (60 μg/mL) for indicated time periods. After TNFα (20 μg/mL) stimulation, cell lysates from each time point were immunoblotted with anti-GLI1, anti-P-p65 (Ser536), and anti-p65 antibodies. (G) GLI1 luciferase reporter analysis of 293T cells transiently transfected with indicated constructs with or without TNFα stimulation for 6 hours. Results are normalized to Renilla luciferase and expressed as fold change in relative luciferase activity compared with control. Data represent the mean and standard deviation of 2 independent experiments (**P < .005). (H) FL-GLI1TM construct was transiently transfected in 293T cells. After 48 hours, cells were stimulated with TNFα (20 μg/mL) for 60 minutes after CHX (60 μg/mL) and MG132 (30 μg/mL) treatment of indicated time periods. Cell lysates from each time point were immunoblotted with anti-GLI1 antibody. (I) 293T cells were cotransfected with full-length GLI1 and GLI1TM mutant construct, and ITCH-IKKβ-GLI1 complex was purified using anti-IKKβ antibody and subjected to immunoblotting. Each component of GLI1 complex immunoblots were analyzed by densitometry, normalized with IKKβ, and plotted to determine normalized ITCH/GLI1 association.

Close Modal

or Create an Account

Close Modal
Close Modal